FINWIRES · TerminalLIVE
FINWIRES

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

By

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.

The company is expected to present results from its phase 1 study of VX-828 in patients with cystic fibrosis in H2, with a positive readout potentially strengthening its competitive advantage in the space, RBC analysts said.

Favorable data will likely result in modest upside, while unfavorable data will likely lead to little downside, the analysts added.

Meanwhile, approval by the US Food and Drug Administration for Vertex's povetacicept in immunoglobulin A nephropathy, with a PDUFA date of Nov. 30, 2026, is likely due to strong interim phase 3 results, the analysts said.

They said that the drug's differentiated profile could make it the preferred choice of most doctors.

With Sionna Therapeutics (SION) failing to demonstrate significant sweat chloride improvements as an add-on to Trikafta, one of the more significant overhangs on Vertex's stock has been removed, according to the note.

RBC's rating on the company's stock is outperform with a price target of $570.

Price: $528.18, Change: $-1.47, Percent Change: -0.28%

Related Articles

Wire

Dateline Resources Says US Court Orders Halt to Operations at California Project in Ongoing Case; Shares Reach One-Year Low

Dateline Resources (ASX:DTR) said the US District Court for the Central District of California issued a preliminary order requiring, among other things, that Dateline and its wholly-owned unit, Colosseum Rare Metals, halt operations at the Colosseum project until either a preliminary injunction is lifted or a final judgment is delivered in relation to the National Parks Conservation Association proceedings, according to a Wednesday Australian bourse filing.The non-governmental organization had brought the proceedings in the court against the US Department of the Interior, the US National Parks Service, and various other parties, per the filing. It sought a preliminary injunction restraining activities at the project pending resolution of its challenge to the 2025 National Parks Service's acknowledgement of the continuing effect of the mine's existing plan of operations.Dateline said it is considering the preliminary order and its alternative courses of action, including a potential appeal to the appellate court.The company's shares fell nearly 38% in recent trading and earlier reached their lowest point in over a year.

ASX:DTR
Wire

Franco-Nevada Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Franco-Nevada (FNV) reported Q2 non-GAAP net income late Tuesday of $1.81 per diluted share, up from $1.24 a year earlier.Analysts polled by FactSet expected $1.96.Revenue in the three months ended June 30 rose to $580.9 million from $369.4 million a year earlier.Analysts expected $616.7 million.The board maintained a quarterly dividend of $0.44 a share, payable Sept. 24 to stockholders of record Sept. 10.The company's shares fell 2.1% in after-hours trading.

$FNV
Wire

ERock Q2 Revenue Falls; 2026 Guidance Set

ERock (EROC), which completed its initial public offering in June, reported Q2 net loss late Tuesday of $0.06 per diluted share. Comparable year-ago details were not provided.Analysts polled by FactSet expected a loss of $0.24.Revenue for the quarter ended June 30 was $39.9 million, down from $68.5 million a year earlier.Four analysts expected $20.4 million.For 2026, the company expects revenue of $435 million to $465 million. Analysts expect $448.3 million.Also, the company highlighted that it executed a 470 megawatt equipment purchase order from Anthropic, extending its production commitments into 2028.

$EROC